Pfizer

Novo Nordisk

Mega Recap: Open Door Alerted before it took off! Your $10k investment could've been worth a whopping $30,000 in just a week! Don't Miss Out on Your Next Exclusive Opportunity!  

Opinion: Pfizer has a high potential upside! the company has made several acquisitions, sitting on a rich pipeline, therefore, the stock is worth accumulating at $22/$23 level.

Exclusive Alert!

 10 Billion Dollar Duel for Metsera, Novo Nordisk vs Pfizer 

📈 Market Roundup - Fat People, Fatter Profits 

  • The global obesity drug market is worth $72 billion today and projected to hit $139 billion by 2030. 

  • Novo Nordisk leads with Ozempic and Wegovy, Eli Lilly surges with Zepbound, and Pfizer is fighting to re-enter the race. 

  • Pfizer faces a looming patent cliff by 2028 for blockbusters like Eliquis, Ibrance, and Prevnar, while COVID revenues continue to decline. 

⚔️ The Battle for Metsera 

  • September 2025: Pfizer announces a deal to buy Metsera for $47.50 per share, valuing the startup at $7.3 billion. 

  • October 2025: Novo Nordisk reopens bidding — rare in pharma — with offers climbing to $10 billion. 

  • November 2025: Pfizer sweetens its bid to $65.60 upfront plus $20.65 in contingent value rights (CVRs) tied to clinical milestones. 

  • Regulatory Edge: The FTC warned Metsera of “unacceptably high risks” in a Novo deal, while Pfizer’s acquisition had already cleared antitrust review. 

  • Outcome: Novo retreats, citing “financial discipline.” Pfizer clinches the deal on November 13, 2025. 

🔍 Why Novo Nordisk Hesitated 

  • Internal turbulence: CEO shake-up and board changes amid investor frustration. 

  • Regulatory scrutiny: U.S. antitrust concerns over its dominance in obesity drugs. 

  • Financial discipline: Reluctance to pay billions for a three-year-old biotech with no approved drugs. 

  • Strategic miscalculation: Novo believed its dominance gave it time — Pfizer proved otherwise. 

🚨 Why Pfizer Was Desperate 

  • Scrapped its own obesity pill, danuglipron, earlier this year. 

  • Needed a growth engine to offset patent expirations and falling COVID sales. 

  • Metsera’s pipeline offered: 

  • GLP-1 receptor agonist in Phase 2 trials. 

  • Two oral pill candidates about to enter trials. 

  • Differentiated dosing and tolerability compared to existing injectables. 

"For Pfizer, Metsera wasn’t optional — it was survival." 

📊 The Fallout 

  • Pfizer: Gains a pipeline expected to deliver launches by 2028–2029, potentially generating $5 billion in peak sales. 

  • Novo Nordisk: Suffers a rare defeat, exposing vulnerabilities as Eli Lilly gains ground. 

  • Investors: Witnessed a rare live auction in pharma, proving that timing, law, and strategy matter as much as science. 

🏁 Bottom Line

Pfizer’s desperation met Novo’s hesitation, and Metsera became the prize that reshaped the battlefield. Novo retreats, Eli Lilly advances, and Pfizer reclaims its place in the obesity arms race. 

Exclusive Alert! Future Fintech

Today’s Newsletter Brought to you by: Future FinTech $FTFT ( ▼ 2.17% )

Future FinTech Group (NASDAQ: FTFT) is a financial and digital technology service provider. The Company conducts asset management, brokage and investment banking services in Hong Kong, operates a cross-border payment business in the United Kingdom, and engages in supply chain trading and finance businesses in China. Please visit their website for more details, thank you!  

Breaking News!

FTFT International Securities & Futures Co., Ltd. ("Future Securities"), has signed a strategic cooperation agreement with MaxQuant AI. As per the agreement, the two parties plan to jointly explore cooperation in financial product innovation and to create an AI-driven intelligence system in financial services to enhance investor experiences.

The MaxQuant AI platform is operated by seasoned IT professionals and a top-tier AI team. After three years of collaboration, the two firms have refined an AI-based sophisticated stock selection platform that upholds the highest standards of professionalism while ensuring regulatory compliance for global investors. In addition, Future Securities plans to launch a '6-Months Free' trial usage campaign for the MaxQuant AI platform, which will allow investors to access all of the platform's features free during this period. 

National Security is in the eye of the beholder! It didn't use to be that way! Americans are totally confused and utterly baffled they don't know what to make of it.  

The so called China Hawks are now Feasting on the Dead, Rotting Sacred Cow like starving Vultures. 

Editors Note: Daily Stock Show planning to release soon an Exclusive Analysis of Tri-Party OpenAI/Oracle/Nvidia Deal and its consequences for the Future of AI.

FTFT - a better way to diversify and benefit from roaring Hong Kong Market!

🧥 The Trend We’re Loving:
AI Super-Talent Poaching Game. Mark Zuckerberg Swallowed more than he can Digest! Latest Mega Funding rounds may rekindle the flames again!

Google Finally Joined the Ultra Exclusive Trillion Dollar Club Sporting $3 Trillion Dollar Crown!

🛒 @TOP10STOCKS: Stocks Under $5 or LESS!

  • Fast Moving Stocks

  • Day Trading, Position Trading

  • Discover High Reward, High Risk, Big Pay Opportunities!

How to Nail 10 Xrs
We believe Gold trade is massively overcrowded it’s time to take profits and reenter around $4K. Tariffs, Rate Cuts & Green Deal Disaster trading strategies offer great opportunies.

  • Rare Earths supplies will remain insufficient for the next 10 years!

  • Uranium is the King of Fuels

  • Wind & Solar on a life support

Don’t be afraid to mix & match — some companies always will have an edge! We Hunt for those Companies!

Nuclear Power Rules The World! 5 Takeaways

  1. Hyperscalers are hungry beasts.

  2. A number of huge grid expansion projects are underway.

  3. America’s Largest Electricity Buildup Since the National Highway Project

  4. Trillion Dollar Project Unvield by OpenAI.

  5. The Bottom Line: Our Analysts believe that it woul be hard for the United States to meet the projectd electricity demand without SMRs.

Novo Nordisk Administers a Huge Doze of Ozempic to Hims & Hers. Ouch!

Novo Nordisk (NVO) abruptly canceled the deal with Hims & Hers (HIMS) which resulted in a sudden drop of more than 30% ! which ironically is much higher than an average patient undergoing Ozempic treatment expect to lose.

Novo Nordisk stock lost so much weight we think it’s time to Feast on it.

Trump to meet Putin in Hungary!

The Europeans have got what they wanted!

“Talk is Cheap, Send Troops, idiots!” the Europeans and their coalition of the willing are a bunch of morons feeding the war machine!

Canada Update! Carney survives the White House visit! High Priests of PR Shops on the Madison Ave and K Street advised Carney to stay on the message, praise Trump profusely and talk big! The visit was successful but nothing has been resolved!

Sweepaways

What’s Trending Now

Intel in play: Huge investment from Nvidia sent Intel stock to the moon!

Ethereum under pressure

Bitcoin whipsawed badly: a whopping $19 Billion wiped out!

Fresh Ideas

Credit Cards are competing for Buy Now Pay Later - May be Never business! Girls are paying for Fake Nails and Guys are buying Condoms! see you later, alligator!

Market Forecasts & Follies

Market is overlooking Tariffs they will soon regret, intrest rate cuts driving the markets higher! Gold, Major Indices are near record highs!

Focus Forward

From crisp minds comes sharp and textured thinking, analyzing the facts, gauging market sentiment, politics and policy implications on every investment move you make matters to your personal bottom line and your future financial freedom. We always keep an eye out for what matters you the most: pairing ideas and trading strategies together — for better outcomes, it’s all about a right mix of contrarian, contrast thinking with an ample dose of idea cohesion.

Outlook

We are committed to extensively cover the emerging challenges and opportunities created by the Big Beautiful Bill so you can preposition yourself to reap the rewards and bag the low hanging fruits before others discover the ground level opportunities.

Future is what we care about!

Plentiful groundlevel opportunities in AI and AI adjacent sector are still available, in addition to investment opportunities in Strategic Metals & Minerals, Transformative Discoveries in Medicine and Stable Coin, Bitcoin, Blockchains, Quantum Computing and Trillion Dollar Private Equity Participation Opportunity, the breadth and scale of investment opportunities have never been great and complexities have never been greater, and that’s why we are committed to bring you the Actionable Intelligence®© that you need to shape your own future and achieve a greater financial freedom!

xoxo,

Reply

or to participate

More From Capital

No posts found